...Good morning, and thank you, everyone, for joining us today. We have never been busy and more excited about our future transformation. Let me start by acknowledging our founder, Al Mann, who passed away 5 years ago today. And it was also the day that I decided to join MannKind and take our journey forward. We would not be here today without his generosity, of him as well as his trustees, to have fully supported us through this transformation over the last 5 years. I want to thank everyone again and look forward to sharing with you the strategic direction we're laying out for 2021 and beyond. I want to go back to what we laid out in January of 2020, and that is our strategy around the focus of endocrine disease and orphan lung. Today, you'll start to see how that starts to shape out and what we did in 2020 to set us up for that direction in the future. Additionally, you can see with our acquisition of Qrum, we'll not be limited by our current proprietary technologies, but we'll look for...